Polymorphic Catecholergic Ventricular Tachycardia

‘Undruggable’ targets aren’t just in oncology. Cardurion Pharmaceuticals is hoping to become the first to successfully develop a treatment for a genetic heart condition that researchers have been studying for decades. The startup is working on a rare heart disease known as catecholaminergic polymorphic ventricular tachycardia — CPVT for short — that can lead to abnormal heart rhythms and is estimated to impact one in 10,000 people. To do so, it’s using a CaMKII inhibitor and has become the first to put such a drug into human studies. It’s not an easy target. CaMKII is a protein kinase that is involved in both heart function and human memory — meaning that any drug going after it has to be extra precise. Cardurion CEO Peter Lawrence told Endpoints News that big pharma companies they are in contact with “were really intrigued by the fact we were able to get into human clinical testing with the CaMKII inhibitor because other major pharmas and biotechs have tried for a very long time — and it was hard to do.” Cardurion’s plan to develop the next generation of heart disease treatments involves a mix of internal research and external hunting. Founded by cardiologist and seasoned industry executive Michael Mendelsohn, who previously led cardiovascular research at Merck Research Laboratories, Cardurion launched in 2017 through a partnership deal with Takeda. As part of that partnership, a cardiovascular research team from Takeda’s site in Shonan, Japan turned into Cardurion’s drug discovery unit. Along with its CaMKII inhibitor, the Massachusetts-based company has clinical trials for heart failure studying two PDE9 inhibitors, one of which was a failed blood disorder treatment that Cardurion is looking to revive. In May, the company touted biomarker results from its Phase 2 study of one of those inhibitors. The company declined to disclose exactly how much money it has raised, beyond saying it’s somewhere north of $500 million. That includes a $260 million Series B that Cardurion announced in July and part of a $300 million commitment from Bain. “What we do is translate our expertise in cardiovascular signaling pathways into therapeutics for our patients. That is the scientific thesis that undergirds everything that we do,” Lawrence said. “We are constantly thinking about what could be attractive targets to pursue in various diseases. And we don’t talk a lot about what we’re looking at, because it’s proprietary, but it is no different than oncology.” Key backers: Ascenta Capital, Blue Owl Capital, Delos Capital, Digitalis Ventures, Farallon Capital Management, Fidelity Management, GV, Millennium Management, New Enterprise Associates, The Invus Group, Bain Capital Life Sciences and Bain Capital Private Equity, Polaris Partners, Takeda Pharmaceuticals Find the full list of 2024 Endpoints 11 winners here .

CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference on Monday, September 30, 2024, at 11:00 am ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page. Institutional investors interested in meeting with management during the conferences may reach out to their Chardan representatives. About Solid BiosciencesSolid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com. Solid Biosciences Investor Contact:Nicole AndersonDirector, Investor Relations and Corporate CommunicationsSolid Biosciences Inc.investors@solidbio.com Media Contact:Glenn SilverFINN Partnersglenn.silver@finnpartners.com

CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 am ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page. Institutional investors interested in meeting with management during the conferences may reach out to their Cantor Fitzgerald representatives. About Solid BiosciencesSolid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com. Solid Biosciences Investor Contact:Nicole AndersonDirector, Investor Relations and Corporate CommunicationsSolid Biosciences Inc.investors@solidbio.com Media Contact:Glenn SilverFINN Partnersglenn.silver@finnpartners.com